Hepaglide 0.5mg Injection

Q1: What is Hepaglide 0.5mg used for?

Hepaglide 0.5mg is the first therapeutic maintenance dose of injectable semaglutide from Zydus Healthcare, providing meaningful weight loss support and glycaemic control for type 2 diabetes after the 4-week 0.25mg initiation phase.

Q2: What clinical benefit can I expect at Hepaglide 0.5mg?

At 0.5mg, most patients notice reduced appetite, earlier satiety, and initial weight loss of 2–4 kg over 4–8 weeks. HbA1c typically falls by 1.2–1.5% over 12–16 weeks in type 2 diabetes patients.

Q3: How does Hepaglide 0.5mg compare with Ozempic 0.5mg?

Hepaglide 0.5mg is bioequivalent to Ozempic 0.5mg in terms of the active ingredient, dose, and expected clinical outcome. Hepaglide is manufactured by Zydus Healthcare to equivalent quality standards at a significantly lower price.

Q4: Can Hepaglide 0.5mg be combined with a DPP-4 inhibitor?

Clinical guidelines generally do not recommend combining a GLP-1 agonist with a DPP-4 inhibitor due to overlapping mechanisms and negligible additive benefit. Replacing the DPP-4 inhibitor with Hepaglide typically provides greater efficacy.

Q5: What if I experience nausea every time I inject Hepaglide 0.5mg?

Persistent nausea is common in the first 4 weeks at a new dose. Eating smaller, lower-fat portions, avoiding rich foods, staying upright after meals, and staying hydrated can help. If nausea is severe or interferes with daily life, contact your prescriber.

Q6: Can Hepaglide 0.5mg be stored in a travel cooler?

Yes. In-use pens can be kept at room temperature (below 30°C) for up to 56 days. Unused pens need 2–8°C storage, achievable with a travel medical cooler or insulated bag with an ice pack (no direct ice contact).

Q7: Is Hepaglide 0.5mg suitable for patients over 70?

Age does not require dose adjustment for semaglutide. However, older adults are more vulnerable to dehydration and adverse GI effects. Close monitoring, adequate fluid intake, and awareness of hypoglycaemia risk with concurrent diabetes medications are important.

Q8: Does Hepaglide 0.5mg improve fatty liver?

Weight loss from semaglutide reduces hepatic fat accumulation (steatosis). Patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) may see improved liver enzyme levels and ultrasonographic changes as weight decreases.

Q9: How do I know the Hepaglide pen is empty?

The dose counter on the pen window will show the remaining dose quantity. When the counter reads 0 or a specific end mark, the pen is empty and should be discarded. Do not attempt to refill or inject from an empty pen.

Q10: Will my prescriber continue Hepaglide at 0.5mg if results are satisfactory?

Yes. If glycaemic and weight-loss goals are met at 0.5mg with acceptable tolerability, there is no obligation to escalate to 1mg. The target dose is always individualised to the minimum effective dose for each patient.